Ye Jia Xi, Wu Jia Ying, Zhu Min, Ai Liang, Huang Qihui
Department of Chinese Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510120, China.
Department of Stomatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510120, China.
Curr Pharm Biotechnol. 2025 Jun 24. doi: 10.2174/0113892010326797250422095516.
The combination of Gardeniae Fructus (ZZ) and Scutellariae Radix (HQ) is a traditional Chinese medicine used for Alzheimer's disease (AD). However, the molecular mechanisms underlying its anti-dementia effects, particularly its multi-component synergy and pathway modulation, remain poorly understood.
Our study employed an integrated systems pharmacology approach to mechanistically decode the anti-AD properties of ZZ-HQ, combining network pharmacology predictions, molecular docking simulations, and experimental validation to identify critical bioactive components, molecular targets, and therapeutic pathways.
A comprehensive network pharmacology analysis was performed to identify bioactive compounds within the ZZ-HQ complex and their potential protein targets associated with AD. Molecular docking was utilized to predict and assess the binding interactions between key bioactive compounds and AD-related protein targets. Experimental validation focused on baicalin, a major active compound in the ZZ-HQ complex, evaluating its effects on cell viability, apoptosis regulation, oxidative stress reduction, and the activation of the PI3K/Akt signaling pathway.
Fifty-four bioactive compounds were identified in the ZZ-HQ complex, interacting with 258 AD-associated proteins. Key compounds, such as baicalein and norwogonin, demonstrated strong binding affinities with pivotal proteins, including SRC and PIK3R1. Experimental studies further confirmed that baicalin significantly improved cell viability by activating the PI3K/Akt pathway, reducing apoptosis, and alleviating oxidative stress.
Our study uncovered the therapeutic potential of the ZZ-HQ combination in addressing AD through multi-target mechanisms, particularly via modulation of the PI3K/Akt pathway and oxidative stress. These findings provide a scientific basis for the pharmacological effects of ZZ-HQ and offer valuable insights for further research on its potential application in AD treatment.
栀子(ZZ)和黄芩(HQ)的组合是一种用于治疗阿尔茨海默病(AD)的传统中药。然而,其抗痴呆作用的分子机制,特别是其多成分协同作用和通路调节,仍知之甚少。
我们的研究采用综合系统药理学方法,从机制上解码ZZ-HQ的抗AD特性,结合网络药理学预测、分子对接模拟和实验验证,以确定关键生物活性成分、分子靶点和治疗途径。
进行了全面的网络药理学分析,以确定ZZ-HQ复合物中的生物活性化合物及其与AD相关的潜在蛋白质靶点。利用分子对接预测和评估关键生物活性化合物与AD相关蛋白质靶点之间的结合相互作用。实验验证集中在ZZ-HQ复合物中的主要活性化合物黄芩苷上,评估其对细胞活力、凋亡调节、氧化应激降低和PI3K/Akt信号通路激活的影响。
在ZZ-HQ复合物中鉴定出54种生物活性化合物,它们与258种AD相关蛋白相互作用。关键化合物,如黄芩素和去甲黄芩苷,与包括SRC和PIK3R1在内的关键蛋白表现出很强的结合亲和力。实验研究进一步证实,黄芩苷通过激活PI3K/Akt通路、减少细胞凋亡和减轻氧化应激,显著提高了细胞活力。
我们的研究揭示了ZZ-HQ组合通过多靶点机制治疗AD的潜力,特别是通过调节PI3K/Akt通路和氧化应激。这些发现为ZZ-HQ的药理作用提供了科学依据,并为其在AD治疗中的潜在应用的进一步研究提供了有价值的见解。